1260433-01-9Relevant academic research and scientific papers
Aminoimidazoles as BACE-1 inhibitors: The challenge to achieve in vivo brain efficacy
Swahn, Britt-Marie,Holenz, J?rg,Kihlstr?m, Jacob,Kolmodin, Karin,Lindstr?m, Johan,Plobeck, Niklas,Rotticci, Didier,Sehgelmeble, Fernando,Sundstr?m, Marie,F?lting, Johanna,Georgievska, Biljana,Gustavsson, Susanne,Neelissen, Jan,Ek, Margareta,Olsson, Lise-Lotte,Berg, Stefan,Berg, Stefan Von
scheme or table, p. 1854 - 1859 (2012/04/17)
The evaluation of a series of bicyclic aminoimidazoles as potent BACE-1 inhibitors is described. The crystal structures of compounds 14 and 23 in complex with BACE-1 reveal hydrogen bond interactions with the protein important for achieving potent inhibit
NOVEL COMPOUNDS FOR TREATMENT OF NEURODEGENERATION ASSOCIATED WITH DISEASES, SUCH AS ALZHEIMER'S DISEASE OR DEMENTIA
-
Page/Page column 55, (2011/02/24)
The present invention relates to novel compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of Aβ-related pathologies such as Downs syndrome, β- amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI ("mild cognitive impairment"), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with diseases such as Alzheimer disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.
